The effect of verapamil on the nephrotoxic potential of gentamicin as measured by urinary enzyme excretion in healthy volunteers
The effects of verapamil on the nephrotoxic potential of multiple-dose gentamicin were studied in healthy adult male volunteers. Subjects received a gentamicin infusion every 8 hours for 19 doses. Gentamicin dosage was adjusted to maintain peak concentrations of 5.5 mg/L and trough concentrations of...
Saved in:
Published in | Journal of clinical pharmacology Vol. 35; no. 2; p. 196 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
England
01.02.1995
|
Subjects | |
Online Access | Get more information |
Cover
Loading…
Abstract | The effects of verapamil on the nephrotoxic potential of multiple-dose gentamicin were studied in healthy adult male volunteers. Subjects received a gentamicin infusion every 8 hours for 19 doses. Gentamicin dosage was adjusted to maintain peak concentrations of 5.5 mg/L and trough concentrations of 0.5 mg/L. Verapamil was given as a sustained release preparation of 180 mg twice daily starting 2 days before the aminoglycoside, and continued for 4 days post-gentamicin therapy. Nephrotoxicity was assessed by measuring 24-hour urinary alanine aminopeptidase excretion (AAP). The urinary AAP results of six subjects given gentamicin with verapamil were compared with urinary AAP from nine subjects treated with gentamicin alone. These nine subjects were matched with the verapamil-treated subjects on the basis of gentamicin area-under-the-curve (AUC). After matching AUC, gentamicin exposure was virtually identical between the two groups with an average gentamicin AUC of 26.61 +/- 1.49 and 27.51 +/- 1.25 mg.hr/L for the gentamicin/ve-rapamil and gentamicin only groups respectively. Verapamil retarded the rise in mean daily AAP excretion on days 1 to 6 of gentamicin therapy, with a significant difference with respect to AAP urinary excretion (P < .05) observed on day 2. There was no significant difference in total cumulative AAP excretion or in the time to return to baseline AAP excretion. Therefore, verapamil was effective in reducing AAP excretion associated with gentamicin therapy. |
---|---|
AbstractList | The effects of verapamil on the nephrotoxic potential of multiple-dose gentamicin were studied in healthy adult male volunteers. Subjects received a gentamicin infusion every 8 hours for 19 doses. Gentamicin dosage was adjusted to maintain peak concentrations of 5.5 mg/L and trough concentrations of 0.5 mg/L. Verapamil was given as a sustained release preparation of 180 mg twice daily starting 2 days before the aminoglycoside, and continued for 4 days post-gentamicin therapy. Nephrotoxicity was assessed by measuring 24-hour urinary alanine aminopeptidase excretion (AAP). The urinary AAP results of six subjects given gentamicin with verapamil were compared with urinary AAP from nine subjects treated with gentamicin alone. These nine subjects were matched with the verapamil-treated subjects on the basis of gentamicin area-under-the-curve (AUC). After matching AUC, gentamicin exposure was virtually identical between the two groups with an average gentamicin AUC of 26.61 +/- 1.49 and 27.51 +/- 1.25 mg.hr/L for the gentamicin/ve-rapamil and gentamicin only groups respectively. Verapamil retarded the rise in mean daily AAP excretion on days 1 to 6 of gentamicin therapy, with a significant difference with respect to AAP urinary excretion (P < .05) observed on day 2. There was no significant difference in total cumulative AAP excretion or in the time to return to baseline AAP excretion. Therefore, verapamil was effective in reducing AAP excretion associated with gentamicin therapy. |
Author | Wojcik, G J Goldfarb, A L Nix, D E Kazierad, D J Schentag, J J |
Author_xml | – sequence: 1 givenname: D J surname: Kazierad fullname: Kazierad, D J organization: State University of New York, Buffalo School of Pharmacy, USA – sequence: 2 givenname: G J surname: Wojcik fullname: Wojcik, G J – sequence: 3 givenname: D E surname: Nix fullname: Nix, D E – sequence: 4 givenname: A L surname: Goldfarb fullname: Goldfarb, A L – sequence: 5 givenname: J J surname: Schentag fullname: Schentag, J J |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/7751432$$D View this record in MEDLINE/PubMed |
BookMark | eNotkMtqwzAQRbVISdO0n1AQ3dsdyZYcL0voCwLdpOugx6h2sGUjyyHuqp9el2Y1F-7hcJkbsvCdR0IeGKQMgD8eUyYET3IJecrKUqRRgwDG0vOCrABKlvAC4JrcDMMRgMlcsCVZFoVgecZX5GdfIUXn0ETaOXrCoHrV1g3tPI1z5bGvQhe7c21o30X0sVbNH_k1xxk0tadqoC2qYQxoqZ7oGGqvwkTRf0_tLD-bgLGefTNaoWpiNdFT14w-Iobhllw51Qx4d7lr8vnyvN--JbuP1_ft0y4xebZhyabgDqVCsE4ilBtrpQOjS5EpaUtrC2W0yS0X2mqRZ4UUmWNaSoGQCZQFX5P7f28_6hbtoQ91O688XD7BfwHP-2Zn |
CitedBy_id | crossref_primary_10_1038_ki_2010_337 crossref_primary_10_1080_105172397243105 crossref_primary_10_1016_S0278_6915_02_00167_9 crossref_primary_10_1016_j_tox_2016_12_003 crossref_primary_10_1111_j_1742_7843_2011_00728_x |
ContentType | Journal Article |
DBID | CGR CUY CVF ECM EIF NPM |
DOI | 10.1002/j.1552-4604.1995.tb05011.x |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) |
DatabaseTitleList | MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | no_fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology |
ExternalDocumentID | 7751432 |
Genre | Research Support, Non-U.S. Gov't Journal Article Comparative Study |
GroupedDBID | --- .55 .GJ 05W 0R~ 123 18M 1CY 1OB 1OC 29K 33P 34G 39C 3O- 3SF 4.4 52U 52V 53G 5RE 8-1 A00 AAESR AAEVG AAHHS AANLZ AAONW AASGY AAWTL AAXRX AAYOK AAZKR ABCUV ABJNI ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACGFO ACGFS ACGOF ACIWK ACMXC ACPOU ACPRK ACXBN ACXME ACXQS ADBBV ADBTR ADEOM ADIZJ ADMGS ADOZA ADXAS AEEZP AEGXH AEIGN AEIMD AENEX AEQDE AEUYR AFBPY AFFNX AFFPM AFGKR AFPWT AFRAH AHBTC AHMBA AI. AIACR AIAGR AITYG AIURR AIWBW AJBDE ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ASPBG ATUGU AUVAJ AVWKF AZFZN AZVAB BDRZF BFHJK BHBCM BMXJE BOGZA BRXPI C45 CAG CGR COF CS3 CUY CVF D-I DCZOG DPXWK DRFUL DRMAN DRSTM DU5 EBD EBS ECM EIF EJD EMOBN F5P FEDTE FUBAC G-S GODZA GWYGA H13 HF~ HGLYW HVGLF IAO IEA IHR INH INR IVC KBYEO LATKE LEEKS LH4 LOXES LSO LUTES LW6 LYRES M4V MEWTI MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM MY~ N9A NPM O66 O9- OVD P2P P2W PALCI PQQKQ R.K RIWAO RJQFR ROL SAMSI SUPJJ SV3 TEORI VH1 WBKPD WH7 WIH WIJ WIK WOHZO WOIKV WPGGZ WXSBR WYJ X7M YCJ ZGI ZXP ZZTAW |
ID | FETCH-LOGICAL-c4381-872fe6ae0df6e098dd6f0cb953a6d9dd7acbc4d25bdb5437653f1b665e035e672 |
ISSN | 0091-2700 |
IngestDate | Sat Sep 28 08:38:08 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 2 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c4381-872fe6ae0df6e098dd6f0cb953a6d9dd7acbc4d25bdb5437653f1b665e035e672 |
PMID | 7751432 |
ParticipantIDs | pubmed_primary_7751432 |
PublicationCentury | 1900 |
PublicationDate | February 1995 |
PublicationDateYYYYMMDD | 1995-02-01 |
PublicationDate_xml | – month: 02 year: 1995 text: February 1995 |
PublicationDecade | 1990 |
PublicationPlace | England |
PublicationPlace_xml | – name: England |
PublicationTitle | Journal of clinical pharmacology |
PublicationTitleAlternate | J Clin Pharmacol |
PublicationYear | 1995 |
SSID | ssj0016451 |
Score | 1.5068103 |
Snippet | The effects of verapamil on the nephrotoxic potential of multiple-dose gentamicin were studied in healthy adult male volunteers. Subjects received a gentamicin... |
SourceID | pubmed |
SourceType | Index Database |
StartPage | 196 |
SubjectTerms | Adolescent Adult CD13 Antigens - urine Delayed-Action Preparations Drug Administration Schedule Gentamicins - administration & dosage Gentamicins - adverse effects Gentamicins - antagonists & inhibitors Half-Life Humans Infusions, Intravenous Kidney Diseases - chemically induced Kidney Diseases - urine Male Verapamil - pharmacology |
Title | The effect of verapamil on the nephrotoxic potential of gentamicin as measured by urinary enzyme excretion in healthy volunteers |
URI | https://www.ncbi.nlm.nih.gov/pubmed/7751432 |
Volume | 35 |
hasFullText | |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LbxMxELZSEFIviFfFW3NAvaQLG-_amz0iHq0KRD2korfKr5WCyG5EA0py4ufwM5lZu-tVaVXgYkW2YyX7fRrPjucbM_ZCGGeVU1mS426W5A6bsipsYkaFVLwQJm0rMX2ayIPj_PBEnAwGv3pZS9-X-qXZXKor-R9UsQ9xJZXsPyDbLYod-BnxxRYRxvavMfYJGeTz_SAlFcUrwgHAsHaIVLNsVjMzXDRLygvyrmcrp5rTmTpdMzP3YcLWE6XYe6vPrTfrOS6-MqRy9OmQXjK5HpJBQzhC6vwlnm2ntlzEuthd5P6D2uBO7In1Nh5KfW6-mFlrmfdj52S28tM6ucR-89VW6pv2Ju1jjFmca8BDzCLY4XJESri0b4d92ZLAN94zqiN_5-0fxt4Xj0VjLwRHrqU5SS8FxboFVWZd9b-EwC3mLQ2KgnxEfu3ghTLcYWSLbRVjsqQTigqF0yqZC38zY_hXsbjtq6t_3Ta7Fda88EbTejbTO-x2AA5ee37dZQNX32O7Rx679R5Mo0TvbA924aiH6n32E4fBkxCaCjoSQlMDkhB6JISOhDQzkhDUGZyTEPQaAgnBkxA6EgJODSSESMIH7Pj9u-mbgyRc65EYqieH-y-vnFQutZV0aTm2Vlap0aXIlLSltYUy2uSWC221yHEDFFk10lIKl2bCyYLvsBt1U7uHDNAA8TI3qUYnNtdZoYXiupTcjaXUIjWP2I5_sqcLX7vlNDzyx1cNPGHbkbBP2c0KTYV7hn7nUj9vQf8NtE6FHA |
link.rule.ids | 786 |
linkProvider | National Library of Medicine |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+effect+of+verapamil+on+the+nephrotoxic+potential+of+gentamicin+as+measured+by+urinary+enzyme+excretion+in+healthy+volunteers&rft.jtitle=Journal+of+clinical+pharmacology&rft.au=Kazierad%2C+D+J&rft.au=Wojcik%2C+G+J&rft.au=Nix%2C+D+E&rft.au=Goldfarb%2C+A+L&rft.date=1995-02-01&rft.issn=0091-2700&rft.volume=35&rft.issue=2&rft.spage=196&rft_id=info:doi/10.1002%2Fj.1552-4604.1995.tb05011.x&rft_id=info%3Apmid%2F7751432&rft_id=info%3Apmid%2F7751432&rft.externalDocID=7751432 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0091-2700&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0091-2700&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0091-2700&client=summon |